News | May 25, 2021
Nanoform and Celanese explore ways to enhance drug delivery
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Applications include detailed scientific rationale and supporting clinical evidence
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Subscribe To Our Newsletter & Stay Updated
